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Ependymomas (EPN) are enigmatic tumors which con-
tinue to present significant management challenges to
clinicians as evidenced by the failure to cure up to 40%
of cases [1]. Recent genomic and epigenomic studies have
identified alterations in DNA copy number, gene expression
[2,3], and methylation [4] and showed that EPN is a hetero-
geneous disease and consists of distinct molecular subtypes.
However, the involvement of the microRNAs (miRNA) and
their influence over mRNA translation into proteins, in
EPN and their contribution to the complexity of the disease
are still poorly understood.
To identify miRNA - mRNA regulatory network, we sys-
tematically evaluated miRNA - mRNA associations using
expression profiles of tumors from 64 EPN patients (mean
age of 13.3 years, Additional file 1: Table S1 for more de-
tails). For each miRNA-mRNA pair, we measured the asso-
ciation between miRNA and mRNA using a Spearman
rank correlation and filtered with sequence-based predicted
miRNA-target interactions of miRanda and TargetScan da-
tabases Additional File 3: Materials and methods [5,6]. We
selected miRNA-mRNA pairs with strong negative correl-
ation (FDR < 0.005, 78,934 pairs) and evidence for target
interaction as predicted by miRanda (score < −0.5), TargetS-
can (context score < −0.2) and evolutionary conservation
(miRanda conservation score > 0.5). We used these thresh-
olds to obtain a high-confidence list of candidate miRNA-
target interactions. The combination of the correlation and
target prediction filters yielded 390 miRNA-mRNA pairs,
significantly more than was expected by chance (P = 5.95 ×
10−08, two-tailed binomial test, x = 390, n = 78,934, p =
3.71 × 10−03 = 28,309 predicted targets/7,623,897 total
pairs). These 390 putative target interactions from EPN
consisted of 107 evolutionarily conserved miRNAs and 305
target mRNAs (Additional file 1: Table S2). Remarkably,
these miRNAs are significantly enriched for oncomiRs/* Correspondence: anbarasu.lourdusamy@nottingham.ac.uk
Children’s Brain Tumour Research Centre, School of Medicine, Queen’s
Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK
© 2015 Lourdusamy et al.; licensee BioMed Ce
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.tumor suppressor miRNAs (2.01 fold enrichment; P =
9.41 × 10−03, Fisher’s exact test. Additional file 2: Figure S1).
They included let-7c, miR-125b, miR-29a/b, miR-15 family
– miR-15a, miR-16, and miR-196 (tumor suppressors
miRNA), miR-18a/b, miR-19a/b, and miR-17 family – miR-
106a/b, miR-17, miR-20a/b, and miR-93 (onco miRNA).
Growing evidences suggest that miR-17 miRNAs are in-
volved in cell proliferation, development, and stem cell dif-
ferentiation [7]. In addition, members of miR-17 directly
target TGFBR2, attenuate TGF-β signaling that regulates
multitude of cellular processes, and is particularly relevant
not only during development, but also in cancer initiation
and progression [7,8]. Targets genes regulated by miRNAs
are enriched for biological processes or pathways such as
multicellular organismal development (GO:0007275; FDR
= 3.31 × 10−04), neuron differentiation (GO:0030182; FDR
= 3.85 × 10−04), regulation of cell adhesion (GO:0030155;
FDR = 3.75 × 10−03), MAPK signalling pathways
(hsa04010; FDR = 2.67 × 10−03), pathways in cancer
(hsa05200; FDR = 3.60 × 10−03), extracellular matrix
(ECM) receptor interaction (hsa04512; FDR = 1.22 × 10
−02), and Integrin, EGF receptor, Wnt, and Neurotro-
phin signaling pathways (Additional file 1: Table S3 ).
Enrichment of known cancer-related processes and
pathways among miRNAs and target genes suggest that
inferred miRNA-target relationships have functional
roles in EPN.
The inferred putative target interactions from EPN
formed a network with 11 highly interconnected sub-
networks (Additional file 2: Figure S2). At least 50 of
the 390 EPN target interactions (comprising 25 miRNAs
and 35 mRNAs) have strong evidence of recurrence in
multiple cancer types (recurrence score < −3.0 and FDR <
0.05) on the basis of The Cancer Genome Atlas (TCGA)
miRNA-target interactions analysis across 10 cancer types
(Figure 1, Additional file 1: Table S2) [9]. EPN interactions
with high recurrence score include pairs such as miR-
18a:CREBL2 (REC score = −10.56; FDR = 1.81 × 10−07),
miR-106b:TGFBR2 (REC = −9.07; FDR = 2.52 × 10−06), and
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Figure 1 Ependymoma network of miRNA-mRNA target interactions. Two highly connected sub-networks from the inferred network of ependymoma
comprising 390 putative target interactions between 107 miRNAs and 305 target mRNAs. Edge width represents strength of Spearman rank correlation
for a given miRNA-mRNA pair, red edge colour represents evidence of recurrence in multiple cancer types, and miRNAs from the same family are color
coded while a single miRNA is shown in white.
Lourdusamy et al. Acta Neuropathologica Communications  (2015) 3:26 Page 2 of 4(REC = −19.74; FDR = 7.05 × 10−15), UBTD2 (REC = −9.97;
FDR = 4.99 × 10−07), and MEX3B (REC = −5.86; FDR =
6.64 × 10−04) that physically interacts with the AGO1 gene,
encoding a member of the Argonaute family of proteins
which play a role in RNA interference by miRNAs via the
RISC complex. The network also showed several novel
EPN-specific interactions with genes that are involved in
axon guidance (miR-29a:LAMA2, miR-29c:LAMA2),
histone H3-K27 methylation (miR-106B:EZH1), chroma-
tin modification (miR-29c:JARID2), and methylation-
dependent chromatin silencing (miR-29a:DNMT3B).
Next, we asked whether the network represented by
these putative target interactions captures the salient
transcriptomic features of EPN subgroups, particularly
from posterior fossa (PF). In line with earlier studies, a
consensus clustering analysis of mRNA expression data
among 64 EPN cases led to the identification of three
transcriptional subtypes: largely supratentorial (ST,
37.5%), PF with spinal (SP) and ST (PF + SP + ST,
29.7%), and largely PF (PF, 32.8%) (Additional file 2:
Figure S3). The group largely associated with PF (named
as PFA) comprised predominantly of children with mean
age of 3.5 years (range from 0.4 – 9.2 years), whereas the
PF clustered with SP and ST (named as PFB) consisted
of adults with a mean age of 24.5 years (range from 8 –
45 years) (Additional file 2: Figure S4). The differential
expression analysis between the two PF subgroupsdetected a total of 46 mRNA targets as significant
(FDR < 0.05), and 27 of these were also differentially
expressed in an independent dataset (P = 6.20 × 10−05,
Fisher’s exact test) of 37 PF EPN from the previously
published study (Additional file 1: Table S4). Remark-
ably, the direction of expression differences between two
PF subgroups was same in both cohorts for all of the 27
overlapping differentially expressed genes (Additional
file 2: Figure S4). Fifteen overlapping mRNA target genes
showed high levels of expression in the PFA subgroup,
of which four (ACSL6, ATP1B2, CAMK2B, and S1PR1)
were regulated by miR-24, four (ADAMTS9, BLMH,
LAMA2, and NUDT11) were regulated by the miR-29
family, three (MMD, PKIA, and STK39) were regulated
by miR-27b, and PDGFRA was regulated by miR-34c
and miR-218. Interestingly, LAMA2 has previously been
identified as a candidate maker gene for PFA subgroup
and associated with poor prognosis [3,10,11]. In
addition to a strong miR29a:LAMA2 association (r = −0.62;
FDR = 1.18 × 10−05), we also observed an inverse correl-
ation between LAMA2 and miR29c (r = −0.49; FDR =
1.61 × 10−03) in EPN, but not in other cancer types
(Figure 2). The two miR-29 family miRNAs are
encoded at two different genomic loci, yet they showed
anti-correlation with LAMA2 in EPN, suggesting EPN-
specific strong co-regulation of the miR-29 loci. Taken
together, these results suggest that downregulation of
Figure 2 miR-29 family regulation of posterior fossa subgroup marker LAMA2. The relationship between LAMA2 mRNA expression and miR-29a (left)
and miR-29c (right) expression in tumor samples from ten different cancer types using Spearman rank correlation, showing strong association only in
EPN. EPN: Ependymoma; GBM: Glioblastoma multiforme; OVA: Ovarian serous cystadenocarcinoma; COAD: Colon and rectal adenocarcinoma;
KIRC: Kidney renal clear cell carcinoma; LUSC: Lung squamous cell carcinoma; BRCA: Breast invasive carcinoma; UCEC: Uterine Corpus Endometrioid
Carcinoma; BLCA: Bladder Urothelial Carcinoma; HNSC: Head and Neck squamous cell carcinoma.
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LAMA2 expression is altered in PF ependymoma.
In summary, we identified miR-29a/c as novel regu-
lators of LAMA2 in ependymoma based on miRNA-
mRNA covariation and sequence-based target predictions.The decreased expression of miR-29a/c and elevated
LAMA2 expression are therefore defining features of
PF ependymoma post-transcriptional regulation, indi-
cating a key mechanism for molecular pathogenesis.
Apart from changes in miRNA expression, other
Lourdusamy et al. Acta Neuropathologica Communications  (2015) 3:26 Page 4 of 4mechanisms (genetic or epigenetic) can contribute to
LAMA2 expression in PF ependymoma, which now
mandates further investigation.
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